News
GYRE
7.69
+4.06%
0.30
Weekly Report: what happened at GYRE last week (0406-0410)?
Weekly Report · 1d ago
Weekly Report: what happened at GYRE last week (0330-0403)?
Weekly Report · 04/06 09:10
Weekly Report: what happened at GYRE last week (0323-0327)?
Weekly Report · 03/30 09:10
Gyre Therapeutics Files NDA in China for F351
TipRanks · 03/23 12:23
Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis
Reuters · 03/23 11:51
Weekly Report: what happened at GYRE last week (0316-0320)?
Weekly Report · 03/23 09:10
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
TipRanks · 03/17 14:15
Gyre Therapeutics’ liver fibrosis candidate granted priority review in China
TipRanks · 03/17 11:20
Gyre Therapeutics Gets Priority Review In China For Hepatitis B Liver Damage Drug
Benzinga · 03/17 11:04
China NMPA grants priority review to Gyre Therapeutics’ Hydronidone NDA for CHB-induced liver fibrosis
Reuters · 03/17 11:02
GYRE THERAPEUTICS INC - CO THROUGH UNIT PANS FORMAL NDA SUBMISSION FOR HYDRONIDONE IN NEAR FUTURE
Reuters · 03/17 11:00
GYRE THERAPEUTICS ANNOUNCES CHINA’S NMPA GRANTS PRIORITY REVIEW TO THE NDA FOR HYDRONIDONE (F351) FOR CHB-INDUCED LIVER FIBROSIS TREATMENT
Reuters · 03/17 11:00
Weekly Report: what happened at GYRE last week (0309-0313)?
Weekly Report · 03/16 09:10
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions
TipRanks · 03/15 06:01
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE)
TipRanks · 03/13 13:10
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE)
TipRanks · 03/12 15:10
BUZZ-U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies
Reuters · 03/12 13:20
BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods
Reuters · 03/12 11:52
BUZZ-Gyre Therapeutics falls on downbeat annual revenue outlook
Reuters · 03/12 11:20
Earnings Scheduled For March 12, 2026
Benzinga · 03/12 11:11
More
Webull provides a variety of real-time GYRE stock news. You can receive the latest news about Gyre Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.